CL2012002081A1 - Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria. - Google Patents

Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.

Info

Publication number
CL2012002081A1
CL2012002081A1 CL2012002081A CL2012002081A CL2012002081A1 CL 2012002081 A1 CL2012002081 A1 CL 2012002081A1 CL 2012002081 A CL2012002081 A CL 2012002081A CL 2012002081 A CL2012002081 A CL 2012002081A CL 2012002081 A1 CL2012002081 A1 CL 2012002081A1
Authority
CL
Chile
Prior art keywords
antibody
procedure
antigen binding
binding protein
protein
Prior art date
Application number
CL2012002081A
Other languages
English (en)
Inventor
Alexander H Taylor
Thomas Matthew Webb
Ian Kirby
Yu Xue
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2012002081A1 publication Critical patent/CL2012002081A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpo humanizado que se une a la cadena alfa del receptor de IL-7 humano (CD127); proteína de enlace a antígeno que comprende una o más regiones determinantes de complementariedad de dicho anticuerpo; molécula de ácido nucleico que codifica una anticuerpo o proteína de enalce; vector de expresión, célula huésped recombinante; procedimiento para la producción de una proteína de enlace a antígeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
CL2012002081A 2010-01-28 2012-07-26 Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria. CL2012002081A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29901010P 2010-01-28 2010-01-28

Publications (1)

Publication Number Publication Date
CL2012002081A1 true CL2012002081A1 (es) 2012-12-14

Family

ID=44320081

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002081A CL2012002081A1 (es) 2010-01-28 2012-07-26 Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.

Country Status (26)

Country Link
US (2) US8940303B2 (es)
EP (1) EP2528947A4 (es)
JP (1) JP5850860B2 (es)
KR (1) KR20130028055A (es)
CN (1) CN102812046B (es)
AR (1) AR080027A1 (es)
AU (1) AU2011209713B2 (es)
BR (1) BR112012018914A2 (es)
CA (1) CA2787070A1 (es)
CL (1) CL2012002081A1 (es)
CO (1) CO6592067A2 (es)
CR (1) CR20120404A (es)
EA (1) EA023700B1 (es)
IL (1) IL220899A (es)
MA (1) MA34004B1 (es)
MX (1) MX339083B (es)
MY (1) MY160590A (es)
NZ (1) NZ601271A (es)
PE (2) PE20170687A1 (es)
PH (1) PH12012501549A1 (es)
SG (1) SG182590A1 (es)
TW (1) TWI489996B (es)
UA (1) UA104663C2 (es)
UY (1) UY33202A (es)
WO (1) WO2011094259A2 (es)
ZA (1) ZA201205624B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858350A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
KR20170065662A (ko) 2014-10-18 2017-06-13 화이자 인코포레이티드 항-il-7r 항체 조성물
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
JP7183042B2 (ja) * 2016-01-07 2022-12-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の免疫炎症性疾患のための治療法
KR102819051B1 (ko) 2016-02-29 2025-06-12 오제 이뮈노테라프틱스 Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
US11098128B2 (en) * 2016-12-09 2021-08-24 Ose Immunotherapeutics Antibodies and polypeptides directed against CD127
WO2019136180A2 (en) * 2018-01-04 2019-07-11 Avidity Biosciences Llc Heteroduplex nucleic acid molecules and uses thereof
EP3914622A1 (en) * 2019-01-22 2021-12-01 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
EP3986570A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
ES3023172T3 (en) 2022-05-30 2025-05-30 Ose Immunotherapeutics Biomarkers of il7r modulator activity
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4646439A1 (en) 2023-01-06 2025-11-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
CN121002069A (zh) 2023-01-06 2025-11-21 泰温治疗私人有限公司 抗原结合分子
EP4455308A1 (en) 2023-04-24 2024-10-30 Les Laboratoires Servier Il-7r gene signatures
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025098341A1 (en) * 2023-11-10 2025-05-15 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US20030229208A1 (en) * 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FI915911A0 (fi) * 1989-06-15 1991-12-16 Immunex Corp Interleukin-7-receptorer.
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
ATE346867T1 (de) * 1994-12-23 2006-12-15 Smithkline Beecham Corp Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1997042329A1 (en) 1996-05-04 1997-11-13 Zeneca Limited Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
CA2280195A1 (en) 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2002541482A (ja) * 1999-04-13 2002-12-03 ヴィレックス アクチェンゲゼルシャフト 診断及び治療のためのウロキナーゼレセプターに対する抗体の使用
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1641818B1 (en) 2003-07-04 2008-12-03 Affibody AB Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
RU2493167C2 (ru) * 2006-12-18 2013-09-20 Дженентек, Инк. АНТИТЕЛА-АНТАГОНИСТЫ ПРОТИВ Notch3 И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С Notch3 ЗАБОЛЕВАНИЙ
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
JP2011509687A (ja) * 2008-01-22 2011-03-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｒｏｎ抗体およびその使用
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos

Also Published As

Publication number Publication date
EA023700B1 (ru) 2016-07-29
JP2013517799A (ja) 2013-05-20
PH12012501549A1 (en) 2016-09-09
EA201290589A1 (ru) 2013-05-30
PE20170687A1 (es) 2017-06-13
MY160590A (en) 2017-03-15
AU2011209713B2 (en) 2014-04-03
US9150653B2 (en) 2015-10-06
EP2528947A2 (en) 2012-12-05
WO2011094259A3 (en) 2011-09-29
US20110200585A1 (en) 2011-08-18
JP5850860B2 (ja) 2016-02-03
UA104663C2 (xx) 2014-02-25
CN102812046A (zh) 2012-12-05
IL220899A0 (en) 2012-09-24
CA2787070A1 (en) 2011-08-04
MX339083B (es) 2016-04-01
IL220899A (en) 2017-08-31
BR112012018914A2 (pt) 2017-07-25
WO2011094259A2 (en) 2011-08-04
US20120282254A1 (en) 2012-11-08
AR080027A1 (es) 2012-03-07
US8940303B2 (en) 2015-01-27
EP2528947A4 (en) 2013-09-18
CN102812046B (zh) 2015-02-25
CO6592067A2 (es) 2013-01-02
SG182590A1 (en) 2012-08-30
ZA201205624B (en) 2014-01-29
AU2011209713A1 (en) 2012-09-13
MA34004B1 (fr) 2013-02-01
TWI489996B (zh) 2015-07-01
PE20121702A1 (es) 2012-12-14
TW201136607A (en) 2011-11-01
UY33202A (es) 2011-08-31
CR20120404A (es) 2012-10-04
MX2012008765A (es) 2012-09-07
KR20130028055A (ko) 2013-03-18
NZ601271A (en) 2014-09-26

Similar Documents

Publication Publication Date Title
MX384418B (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
JOP20200078B1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
CO7250445A2 (es) Proteínas de unión a antígeno st2
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201890169A1 (ru) Тау-связывающие антитела
BR112012009854A8 (pt) proteínas de ligação de antígeno il-23 humana
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
EA201691027A1 (ru) Модуляторы aplnr и их применение
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
EA201492101A1 (ru) Антитела против fcrn
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
EA201690503A1 (ru) Антитела
CL2013001468A1 (es) Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
CL2014000699A1 (es) Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
CL2009000567A1 (es) Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer.
CO7160115A2 (es) Proteinas de unión a antigeno que se unen a pd-l1
EA201500876A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
MX377344B (es) Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
JO3788B1 (ar) تراكيب جسم مضاد لـ egfrviii وcd3
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
CL2014000134A1 (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina.